Breast, pancreatic, and prostate cancers have a disproportionately higher rate of aggressive tumor grade in the target ...

Fintel reports that on March 25, 2025, Stephens & Co. downgraded their outlook for Akoya Biosciences (NasdaqGS:AKYA) from ...

Quanterix sees growth with Akoya acquisition, but rising losses and investor skepticism persist. Explore challenges and ...

Akoya Biosciences (AKYA) and SAMBAI announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology ...

Akoya Biosciences (NASDAQ:AKYA – Get Free Report)‘s stock had its “equal weight” rating restated by stock analysts at ...

Stephens downgraded Akoya Biosciences (AKYA) to Equal Weight from Overweight with a price target of $1.80, down from $3.50, given the pending ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) saw a large decline in short interest in March. As of March 15th, there was short interest totalling 2,490,000 shares, a decline of 30.8% from ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA),announced Wednesday that its PhenoCycler-Fusion system has been chosen as the foundational spatial proteomics technology for a groundbreaking cancer ...